LOG IN
SIGN UP
MARKET
CBIO
CBIO
Catalyst Biosciences Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.230
+0.120
+10.81%
After Hours: 1.240 +0.01 +0.81% 18:46 05/27 EDT
OPEN
1.140
PREV CLOSE
1.110
HIGH
1.230
LOW
1.070
VOLUME
4.67M
TURNOVER
0
52 WEEK HIGH
5.20
52 WEEK LOW
0.3501
MARKET CAP
38.72M
P/E (TTM)
-0.4825
1D
5D
1M
3M
1Y
5Y
The Petri Dish: NIH gives $68M to Pfizer-partnered AI startup
A roindup of companies developing drugs and devices, inking new partnership deals, raising money, expanding facilities and more.
American City Business Journals · 1d ago
BRIEF-Jds1 Llc - Calls Upon Catalyst Biosciences To Schedule 2022 Annual Meeting And Fix The Associated Record Date Therefor
reuters.com · 2d ago
BGFV, TWOU and ASO among pre market losers
Verrica Pharmaceuticals (VRCA) -54% downgraded at RBC as FDA snubs skin disease therapy. Super Group (SGHC) -14% on Q1 results. DICK'S Sporting Goods (DKS) -13% on dire forecast for full-year sales. Better Therapeutics (BTTX) -13%. Academy
Seekingalpha · 2d ago
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers CynergisTek, Inc. (NYSE: CTEK) jumped 100% to $1.18 after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7 million.
Benzinga · 3d ago
Short Volatility Alert: Catalyst Biosciences
On Modnay, shares of Catalyst Biosciences, Inc. (NASDAQ: CBIO) experienced volatile short activity. After the activity, the stock price went up +234.21% to $1.27. The overall sentiment for CBIO has been Bearish.
Benzinga · 3d ago
25 Stocks Moving in Tuesday's Pre-Market Session
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 136.4% to $1.43 in pre-market trading. BOQI International recently posted a Q1 loss of $0.27 per share.
Benzinga · 3d ago
58 Biggest Movers From Yesterday
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.
Benzinga · 3d ago
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Investor Place · 4d ago
No Data
Learn about the latest financial forecast of CBIO. Analyze the recent business situations of Catalyst Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 4 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CBIO stock price target is 11.33 with a high estimate of 16.00 and a low estimate of 3.000.
Current 1.230
EPS
Actual
Estimate
-0.64-0.48-0.32-0.16
Institutional Holdings
Institutions: 85
Institutional Holdings: 17.19M
% Owned: 54.60%
Shares Outstanding: 31.48M
TypeInstitutionsShares
Increased
11
4.26M
New
12
1.31M
Decreased
15
1.61M
Sold Out
27
7.30M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Augustine Lawlor
President/Chief Executive Officer/Director
Nassim Usman
Chief Financial Officer/Senior Vice President - Finance/Chief Accounting Officer
Seline Miller
Senior Vice President
Tom Knudsen
Chief Scientific Officer
Grant Blouse
Director
Jeanne Jew
Independent Director
Errol De Souza
Independent Director
Andrea Hunt
Independent Director
Geoffrey Ling
Independent Director
Sharon Tetlow
Independent Director
Edward Williams
No Data
No Data
About CBIO
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.
Webull offers kinds of Catalyst Biosciences Inc stock information, including NASDAQ:CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading CBIO stock methods without spending real money on the virtual paper trading platform.